Santen Pharmaceutical (OTCMKTS:SNPHY) Stock Rating Upgraded by Mizuho

Mizuho upgraded shares of Santen Pharmaceutical (OTCMKTS:SNPHY) from a neutral rating to a buy rating in a report published on Monday, The Fly reports.

SNPHY opened at $13.89 on Monday. The firm has a fifty day moving average price of $13.31. Santen Pharmaceutical has a 1 year low of $12.50 and a 1 year high of $20.93.

About Santen Pharmaceutical

Santen Pharmaceutical Co, Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase 2b clinical trial; DE-128 in Europe, as well as is in Phase 2/3 clinical trial in the United States; and DE-130A that is in Phase III clinical trial.

Recommended Story: Market Timing – The Benefits and the Danger

The Fly logo

Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with's FREE daily email newsletter.